Chiltern Announces Partnership With Charles River

LONDON, February 22, 2010 - Chiltern International Limited, a global contract research organization
(CRO), announced its latest collaboration with Charles River Laboratories,
Inc. As part of this collaboration, Chiltern Early Phase will partner with
Charles River to conduct and support early phase radiolabelled studies.

Glenn Kerkhof, Chiltern CEO, stated, "This new partnership is an exciting
collaboration. Charles River's reputation is world-renowned for their conduct
of studies using radiolabelled investigational products. Their extensive
experience includes submission and review procedures for radiolabelled
studies in man, including dosimetry calculations and submission to ARSAC. The
clinical aspects of the radiolabelled studies will be performed by Chiltern
Early Phase in Dundee, Scotland. These complementary strengths add a new
dimension to the full CRO services that Chiltern already provides, continuing
to demonstrate our commitment to providing our clients with the highest
standard of quality and expertise."

Chiltern Early Phase has a dedicated 42-bed clinical pharmacology unit
located in a UK National Health Service hospital and leading medical school.
Established in 1982, Chiltern Early Phase has performed more than 700
clinical pharmacology studies in all routes of administration across major
therapeutic areas. With more than 27 years of experience, Chiltern Early
Phase has robust processes in place and its hospital-based location provides
a full suite of safety monitoring with 24/7 access to hospital-based crash
teams and hospital specialists for therapeutic area expertise and patient
recruitment. In addition, Chiltern Early Phase offers an extensive database
of healthy volunteers and other patient populations. Chiltern Early Phase's
long pedigree in clinical pharmacology combined with Charles River's
radiolabel capabilities are poised to provide the industry with unrivalled
experience and expertise in early phase radiolabelled ADME studies.

The Metabolism and Pharmacokinetics group at Charles River, Edinburgh,
have been conducting radiolabelled trials in man for more than 20 years. The
facility includes a GMP clean room, licensed for the manufacture of
radiolabelled drug products, including aseptic products for parenteral use.
The close proximity of the laboratories allows a rapid turn around of
radioactivity data (within 24 hours). Human metabolites can also be
characterised by liquid chromatography with accurate mass, mass spectroscopy
and concurrent radio-detection.

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing international
Phase I to Phase IV clinical trials across a broad range of therapeutic areas
for a wide variety of clients. Chiltern has conducted trials in more than 40
countries, has 26 offices and legal entities within 19 countries, resources
in 37 countries and employs nearly 1,400 people globally. Chiltern provides
Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and
Regulatory Affairs and Resourcing Solutions services. Further information is
available at www.chiltern.com.

    For More Information Contact:

    Natalie Chong                              Sue Ojanen
    Marketing Director                         Marketing Associate
    Chiltern International Ltd.                Chiltern International Inc.
    171 Bath Road                              1241 Volunteer Parkway
    Slough                                     Suite 950
    Berkshire SL1 4AA                          Bristol, TN 37620
    UNITED KINGDOM                             USA
    Tel: +44-(0)-1753-512-000                  Tel: +1-423-968-9533
    Fax: +44-(0)-1753-511-116                  Fax: +1-423-968-3567
    Email: natalie.chong@chiltern.com          Email: sue.ojanen@chiltern.com

Natalie Chong, Marketing Director of Chiltern International Ltd., +44-(0)-1753-512-000, fax, +44-(0)-1753-511-116, natalie.chong at chiltern.com; or Sue Ojanen, Marketing Associate of Chiltern International Inc., +1-423-968 9533, fax, +1-423-968-3567, sue.ojanen at chiltern.com